Dr. Carolyn Britten on Next Steps in Immunotherapy

Carolyn D. Britten, MD
Published: Tuesday, Sep 15, 2015



Carolyn D. Britten, MD, chief, Division of Hematology Oncology, associate director, Clinical Investigations, at the Hollings Cancer Center, Medical University of South Carolina, discusses questions that remain in immunotherapy.
 
Immunotherapy offers a lot of promise to the field of oncology, says Britten, but it is not the only option. Other types of novel therapies are necessary.  
 
Proper patient selection will be the key to best utilizing immune checkpoint blockage therapies, she says. A better understanding of which combinations work best is also needed.     


Carolyn D. Britten, MD, chief, Division of Hematology Oncology, associate director, Clinical Investigations, at the Hollings Cancer Center, Medical University of South Carolina, discusses questions that remain in immunotherapy.
 
Immunotherapy offers a lot of promise to the field of oncology, says Britten, but it is not the only option. Other types of novel therapies are necessary.  
 
Proper patient selection will be the key to best utilizing immune checkpoint blockage therapies, she says. A better understanding of which combinations work best is also needed.     



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x